Why is it so difficult to stop psychiatric drug treatment?: It may be nothing to do with the original problem
Introduction
Although long-term drug treatment is recommended for most patients with schizophrenia, bipolar disorder, recurrent depression and many other psychiatric conditions, there are many reasons to stop or reduce this medication. Firstly, patients may request to do so. Secondly, doses may be excessive. Evidence concerning neuroleptics, for example, suggests that patients often receive doses that exceed the maximally effective range [1]. Thirdly, it has long been believed that some patients with psychosis do not need long-term drug treatment, especially those with good prognostic features [2], and some authors have suggested that most patients do not benefit from such treatment [3]. Elsewhere I have suggested that antidepressants do not have specific effects on depression that warrant their short or long-term use [4], [5].
My clinical experience suggests that even small reductions in drug treatments are frequently problematic. This is usually attributed to the re-emergence of the underlying disorder in the absence of treatment and used to justify the need for recommencing or increasing drugs. However, there is a considerable body of research that suggests that there are intrinsic problems related to the process of withdrawal from long-term psychotropic drug treatment.
Section snippets
Hypothesis
This paper suggests that the problems that occur after withdrawal of psychiatric drugs may often be related to the process of withdrawal of that medication, rather than the natural course of the underlying condition. If this is the case, then the recurrent nature of psychiatric disorders may be partially attributable to the iatrogenic effects of psychiatric drugs. In addition, it calls for re-interpretation of the trial evidence that forms the basis of recommendations for long-term treatment in
Somatic discontinuation syndromes (also known as withdrawal or rebound reactions)
These syndromes refer to physiological and psychological manifestations of the biological effects caused by the withdrawal of a regularly administered drug. These syndromes have been conceptualised as a result of the biological adaptations to continued drug exposure, which become suddenly unopposed when drugs are withdrawn. It is now recognised that discontinuation or withdrawal syndromes occur with many classes of drugs, not just drugs of abuse, including antidepressants [6], [7] and
Mechanisms of withdrawal related disorders
Two possible mechanisms for withdrawal related disorders are suggested by the preceding evidence.
Implications for maintenance treatment
Since all the adverse effects outlined above may be mistaken for re-emergence of underlying illness, evidence on the value of maintenance drug treatment in psychiatry needs to be re-evaluated. Maintenance studies involve a group of people who have been taking medication for some time. Such people are then randomised either to continue medication or to have it withdrawn and replaced by placebo, usually quite rapidly. Hence, the placebo group are in reality a “medication withdrawal” group and are
Implications for management of drug discontinuation
Research shows that a proportion of people even with severe psychotic disorders (somewhere between 20% and 40% [26], [36]) can stop long-term drug treatment without difficulty. If withdrawal related morbidity could be managed effectively, then the outcome of drug discontinuation might be more successful. For psychotic episodes brought on by drug withdrawal some combination of short-term drug therapy, psychological therapy and social support might be necessary. For other problems, including the
Acknowledgements
I thank Professor Ross Baldessarini and Dr. Philip Thomas for helpful comments on the contents of this paper.
References (36)
The case against antipsychotic drugs: a 50-year record of doing more harm than good
Med Hypotheses
(2004)- et al.
Lithium discontinuation: withdrawal or relapse?
Compr Psychiat
(1988) Protracted withdrawal syndromes from benzodiazepines
J Subst Abuse Treat
(1991)Psychopathology induced by “speed drugs”
Pharmacol Biochem Behav
(1981)The nocebo phenomenon: concept, evidence, and implications for public health
Prev Med
(1997)- et al.
First, vs. multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies
Schizophr Res
(2002) - et al.
The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment
J Psychiat Res
(1998) - et al.
Dose response and dose equivalence of antipsychotics
J Clin Psychopharmacol
(2004) - et al.
The treatment of acute schizophrenia without drugs: an investigation of some current assumptions
Am J Psychiat
(1977) - et al.
Efficacy of antidepressants in adults
BMJ
(2005)
Antidepressant withdrawal syndromes: phenomenology and pathophysiology
Int Clin Psychopharmacol
Antidepressant discontinuation: a review of the literature
J Clin Psychiat
Withdrawal syndromes associated with antipsychotic drugs
Am J Psychiat
Neuroleptic discontinuation syndromes
J Psychopharmacol
Dependence on benzodiazepines
J Clin Psychiat
Effects of lithium discontinuation
Bipolar Disord
Cited by (55)
Attempting to discontinue antipsychotic medication: Withdrawal methods, relapse and success
2018, Psychiatry ResearchCitation Excerpt :Discontinuation can entail a range of somatic, emotional, and cognitive withdrawal effects, and psychotic or manic relapse during the withdrawal period is common among those with schizophrenia spectrum and bipolar diagnoses (Salomon and Hamilton, 2013; Gilbert et al., 1995; Harrow et al., 2012; Moncrieff, 2013; Boonstra et al., 2011; Gilbert et al., 1995; Harrow et al., 2012; Buchanan et al., 1992; Moncrieff, 2006a). Little is known of whether psychotic or manic symptoms emerge during withdrawal following off-label use, but it may be common for the symptoms that were the original treatment targets to reappear during or following withdrawal of off-label AMs (Moncrieff, 2006b). In one study of 18 people with OCD who discontinued AM while continuing with an antidepressant, 83.3% reported a relapse of OCD symptoms, most within eight weeks of discontinuation (Maina et al., 2003).
Withdrawal symptoms after discontinuation of a noradrenergic and specific serotonergic antidepressant: A case report and review of the literature
2017, Personalized Medicine in PsychiatryCitation Excerpt :Withdrawal from CNS drugs produces psychiatric symptoms that can be confounded with relapses or recurrences of the original illness [1]. Thus, when withdrawal occurs, it must be identified to avoid prolonging treatments or giving unnecessary high pharmacological doses [3]. Only few papers (only case reports) referred to withdrawal symptoms induced by the discontinuation of antidepressants different from SSRIs and SNRIs.
A psychological flexibility model of medication adherence in psychotic-spectrum disorders
2016, Journal of Contextual Behavioral ScienceCitation Excerpt :A recent study showed that patients with psychotic-spectrum disorders who refused to take antipsychotic medications showed improved clinical outcomes when provided with cognitive behavior therapy for psychosis alone, which was comparable in magnitude to antipsychotic medication effects (Morrison et al., 2014). Nevertheless, it is important to note that abrupt self-discontinuation of antipsychotic medication once a person is already taking them often produces “rebound” symptom effects due in a large part to an antipsychotic withdrawal syndrome (Chouinard & Chouinard, 2008; Margolese, Chouinard, Beauclair, & Belanger, 2002; Moncrieff, 2006). Indeed, abrupt antipsychotic discontinuation is associated with a three-fold increased risk for relapse in schizophrenia (Weiden, Kozma, Grogg, & Locklear, 2004).
Therapeutic equivalence of antipsychotics and antidepressants - A systematic review
2016, Pharmacological ReportsCitation Excerpt :After a long-term treatment with antipsychotics, discontinuation syndromes can produce psychiatric symptoms that can be mistaken for a true relapse of the disease. The drug-induced effect is known as “supersensitivity psychosis”[32]. It can occur within 6 weeks following either a decrease or a complete withdrawal of an oral antipsychotic [33].
Research on a 'drug-centred' approach to psychiatric drug treatment: Assessing the impact of mental and behavioural alterations produced by psychiatric drugs
2018, Epidemiology and Psychiatric SciencesLater is not necessarily better: limitations of survival analysis in studies of long-term drug treatment of psychiatric conditions
2022, BMJ Evidence-Based Medicine